Parallel Bio
Using the immune system to cure disease
Parallel Bio was founded in 2021, is headquartered in Cambridge, United States, lists 1–10 employees, and has $4.3M in recorded funding across 2 rounds.
- Headquarters
- Cambridge, Massachusetts
- Employees
- 1–10
- Founded
- 2021
- Website
- parallel.bio
- Total Funding
- $4.3M
- Last Round
- Series AJun 2025
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 1 investor for this company. The full record is or through the API.
About
Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients. Our platform has all of the same elements as a human immune system, meaning you can test drugs and vaccines as if you were testing them in actual patients from the start. The biggest reason why 95% of new drugs fail is that they were tested in mice - but with our human platform, pharma companies will know which drugs will successfully treat patients, speeding up the process and reducing the cost. To date our platform has successfully been used to test 12 drugs, and vaccines against 8 different diseases. The company is founded by Robert DiFazio, a former Stanford R&D director with a PhD in immunology, and Juliana Hilliard, a former System1 Biosciences R&D lead with an MSc in bioengineering, both of whom have led drug discovery programs for years.
Summary
Parallel Bio is a Biotech company based in Cambridge, United States, founded in 2021. It lists 1–10 employees. It has raised $4.3M in total across 2 rounds, most recently a Series A round in Jun 2025. Investors include Y Combinator.
Tech & App Stack
5 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jun 2025
Sign up to see all 2 events
Funding: Seed through Series A. Amounts, valuations, and investors where available.
Investors
Similar Companies
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intellig...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/parallelbio"><img src="https://indexed.vc/api/badge/company/parallelbio" alt="Parallel Bio on Indexed.vc" width="260" height="76" /></a>